Plasmablastic lymphoma: from genetics to treatment

References

• Swerdlow SC, E, Harris NL, Jaffe ES, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer (IARC). Revised 4th ed.; 2017.
   Google Scholar
• Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89(4):1413–1420.
   PubMed Web of Science ®Google Scholar
• Frontzek F, Staiger AM, Zapukhlyak M, et al. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun. 2021;12(1):5183.
   PubMed Web of Science ®Google Scholar
• Liu Z, Filip I, Gomez K, et al. Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway. Blood Cancer Discov. 2020;1(1):112–125.
   PubMedGoogle Scholar
• Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125(15):2323–2330.
   PubMed Web of Science ®Google Scholar
• Vega F, Chang CC, Medeiros LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005;18(6):806–815.
   PubMed Web of Science ®Google Scholar
• Morscio J, Dierickx D, Nijs J, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol. 2014;38(7):875–886.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Furman M, Beltran BE, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012;118(21):5270–5277.
   PubMed Web of Science ®Google Scholar
• Tchernonog E, Faurie P, Coppo P, et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017;28(4):843–848.
   PubMed Web of Science ®Google Scholar
• Schommers P, Wyen C, Hentrich M, et al. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the german AIDS-related lymphoma cohort study. AIDS. 2013;27(5):842–845.
   PubMed Web of Science ®Google Scholar
• NCCN clinical practices guidelines in oncology (NCCN guidelines), B-cell lymphomas. Version 4.2021; 2021.
   Google Scholar
• Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34(11):1686–1694.
   PubMed Web of Science ®Google Scholar
• Garcia-Reyero J, Martinez Magunacelaya N, Gonzalez de Villambrosia S, et al. Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. Haematologica. 2020;106(4): 1120–1128. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018103.
   Web of Science ®Google Scholar
• Ramis-Zaldivar JE, Gonzalez-Farre B, Nicolae A, et al. MAP-kinase and JAK-STAT pathways dysregulation in plasmablastic lymphoma. haematol. 2021;106(10):2682–2693.
   PubMed Web of Science ®Google Scholar
• Witte HM, Kunstner A, Hertel N, et al. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. Blood Adv. 2022;6(2):637–651.
   PubMed Web of Science ®Google Scholar
• Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(Pt 8):1281–1283.
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32(21):2601–2613.
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr. STATs and gene regulation. Science. 1997;277(5332):1630–1635.
   PubMed Web of Science ®Google Scholar
• Crescenzo R, Abate F, Lasorsa E, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27(4):516–532.
   PubMed Web of Science ®Google Scholar
• Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905–1913.
   PubMed Web of Science ®Google Scholar
• Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048–3057.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407.
   PubMed Web of Science ®Google Scholar
• Ohgami RS, Ma L, Monabati A, et al. STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica. 2014;99(7):e105–e107.
   PubMed Web of Science ®Google Scholar
• Dolcetti R, Gloghini A, Caruso A, et al. A lymphomagenic role for HIV beyond immune suppression? Blood. 2016;127(11):1403–1409.
   PubMed Web of Science ®Google Scholar
• Nicolae A, Xi L, Pham TH, et al. Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas. Leukemia. 2016;30(11):2245–2247.
   PubMed Web of Science ®Google Scholar
• Wenzel SS, Grau M, Mavis C, et al. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia. 2013;27(6):1381–1390.
   PubMed Web of Science ®Google Scholar
• Sansone P, Bromberg J. Targeting the interleukin-6/jak/stat pathway in human malignancies. J Clin Oncol. 2012;30(9):1005–1014.
   PubMed Web of Science ®Google Scholar
• Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103–119.
   PubMed Web of Science ®Google Scholar
• Lowenstein EJ, Daly RJ, Batzer AG, et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell. 1992;70(3):431–442.
   PubMed Web of Science ®Google Scholar
• Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature. 1990;348(6297):125–132.
   PubMed Web of Science ®Google Scholar
• Leevers SJ, Paterson HF, Marshall CJ. Requirement for ras in raf activation is overcome by targeting raf to the plasma membrane. Nature. 1994;369(6479):411–414.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116–120.
   PubMed Web of Science ®Google Scholar
• Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91–101.
   PubMed Web of Science ®Google Scholar
• Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911–3920.
   PubMed Web of Science ®Google Scholar
• Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129(7):1287–1292.
   PubMed Web of Science ®Google Scholar
• Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399–405.
   PubMed Web of Science ®Google Scholar
• Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62(23):6997–7000.
   PubMed Web of Science ®Google Scholar
• Trahey M, McCormick F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science. 1987;238(4826):542–545.
   PubMed Web of Science ®Google Scholar
• Scheffzek K, Ahmadian MR, Kabsch W, et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic ras mutants. Science. 1997;277(5324):333–338.
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–867.
   PubMed Web of Science ®Google Scholar
• Dankner M, Rose AAN, Rajkumar S, et al. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37(24):3183–3199.
   PubMed Web of Science ®Google Scholar
• Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678–689.
   PubMed Web of Science ®Google Scholar
• Kovall RA, Gebelein B, Sprinzak D, et al. The canonical notch signaling pathway: structural and biochemical insights into shape, sugar, and force. Dev Cell. 2017;41(3):228–241.
   PubMed Web of Science ®Google Scholar
• Meurette O, Mehlen P. Notch signaling in the tumor microenvironment. Cancer Cell. 2018;34(4):536–548.
   PubMed Web of Science ®Google Scholar
• Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269–271.
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101–105.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Baldoni S, Rosati E, et al. A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol. 2009;146(6):689–691.
   PubMed Web of Science ®Google Scholar
• Seegmiller AC, Wang HY, Hladik C, et al. Uniform expression of Notch1, suppressor of B-cell-specific gene expression, in plasmablastic lymphoma. Arch Pathol Lab Med. 2011;135(6):770–775.
   PubMed Web of Science ®Google Scholar
• Dent AL, Shaffer AL, Yu X, et al. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 1997;276(5312):589–592.
   PubMed Web of Science ®Google Scholar
• Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000;95(6):2084–2092.
   PubMed Web of Science ®Google Scholar
• Klein U, Casola S, Cattoretti G, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol. 2006;7(7):773–782.
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454(7201):226–231.
   PubMed Web of Science ®Google Scholar
• Mondala PK, Vora AA, Zhou T, et al. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell Stem Cell. 2021;28(4):623–636.e9.
   PubMed Web of Science ®Google Scholar
• Weilemann A, Grau M, Erdmann T, et al. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. Blood. 2015;125(1):124–132.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Rapana B, Olivo K, et al. IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. Br J Haematol. 2010;148(1):115–118.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Papenhausen P, Shao H. The role of c-MYC in B-Cell lymphomas: diagnostic and molecular aspects. Genes. 2017;8(4):116.
   PubMed Web of Science ®Google Scholar
• Chapman J, Gentles AJ, Sujoy V, et al. Gene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programs. Leukemia. 2015;29(11):2270–2273.
   PubMed Web of Science ®Google Scholar
• Montes-Moreno S, Martinez-Magunacelaya N, Zecchini-Barrese T, et al. Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. Mod Pathol. 2017;30(1):85–94.
   PubMed Web of Science ®Google Scholar
• Witte HM, Hertel N, Merz H, et al. Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients. Blood Cancer J. 2020;10(5):63.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412(6844):341–346.
   PubMed Web of Science ®Google Scholar
• Walker BA, Wardell CP, Murison A, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6:6997.
   PubMed Web of Science ®Google Scholar
• Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005;436(7052):807–811.
   PubMed Web of Science ®Google Scholar
• Salghetti SE, Kim SY, Tansey WP. Destruction of myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize myc. EMBO J. 1999;18(3):717–726.
   PubMed Web of Science ®Google Scholar
• Li WX. Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol. 2008;18(11):545–551.
   PubMed Web of Science ®Google Scholar
• Kiuchi N, Nakajima K, Ichiba M, et al. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med. 1999;189(1):63–73.
   PubMed Web of Science ®Google Scholar
• Kerkhoff E, Houben R, Loffler S, et al. Regulation of c-myc expression by ras/raf signalling. Oncogene. 1998;16(2):211–216.
   PubMed Web of Science ®Google Scholar
• Sears R, Leone G, DeGregori J, et al. Ras enhances myc protein stability. Mol Cell. 1999;3(2):169–179.
   PubMed Web of Science ®Google Scholar
• Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006;20(15):2096–2109.
   PubMed Web of Science ®Google Scholar
• Reilley MJ, McCoon P, Cook C, et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018;6(1):119.
   PubMedGoogle Scholar
• Mine S, Hishima T, Suganuma A, et al. Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets. Sci Rep. 2017;7(1):10188.
   PubMedGoogle Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. Inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862.
   PubMed Web of Science ®Google Scholar
• Lito P, Solomon M, Li LS, et al. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016;351(6273):604–608.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371–2381.
   PubMed Web of Science ®Google Scholar
• Andrulis M, Lehners N, Capper D, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013;3(8):862–869.
   PubMed Web of Science ®Google Scholar
• Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80–93.
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431–435.
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427–430.
   PubMed Web of Science ®Google Scholar
• Carras S, Regny C, Peoc’h M, et al. Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma. Leuk Lymphoma. 2015;56(10):2986–2988.
   PubMed Web of Science ®Google Scholar
• Ando K, Imaizumi Y, Kobayashi Y, et al. Bortezomib- and lenalidomide-based treatment of refractory plasmablastic lymphoma. Oncol Res Treat. 2020;43(3):112–116.
   PubMed Web of Science ®Google Scholar
• Posternak V, Cole MD. Strategically targeting MYC in cancer. F1000Research. 2016;5:408.
   Google Scholar
• Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904–917.
   PubMed Web of Science ®Google Scholar
• Chipumuro E, Marco E, Christensen CL, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159(5):1126–1139.
   PubMed Web of Science ®Google Scholar
• Mori H, Fukatsu M, Ohkawara H, et al. Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review. Int J Hematol. 2021;114(6):639–652.
   PubMed Web of Science ®Google Scholar
• Fiorino AS, Atac B. Paraproteinemia, plasmacytoma, myeloma and HIV infection. Leukemia. 1997;11(12):2150–2156.
   PubMed Web of Science ®Google Scholar
• Hummel M, Anagnostopoulos I, Korbjuhn P, et al. Epstein-Barr virus in B-cell non-Hodgkin’s lymphomas: unexpected infection patterns and different infection incidence in low- and high-grade types. J Pathol. 1995;175(3):263–271.
   PubMed Web of Science ®Google Scholar
• Iida S, Rao PH, Butler M, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997;17(2):226–230.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood. 2001;98(10):3082–3086.
   PubMed Web of Science ®Google Scholar
• Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA. 2000;97(1):228–233.
   PubMed Web of Science ®Google Scholar
• Walker BA, Leone PE, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15):e56–e65.
   PubMed Web of Science ®Google Scholar
• Liu Y, Jelloul F, Zhang Y, et al. Genetic basis of extramedullary plasmablastic transformation of multiple myeloma. Am J Surg Pathol. 2020;44(6):838–848.
   PubMed Web of Science ®Google Scholar